Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis
Introduction and hypothesis
Treatment persistence is low in patients with overactive bladder (OAB), but persistence may vary among antimuscarinic agents. This study compared treatment persistence in patients with OAB receiving fesoterodine, solifenacin, or tolterodine as their initial OAB prescription in a routine clinical practice setting.
This retrospective study used medical records from primary healthcare centers in three locations in Spain; records from patients aged ≥18 years with a diagnosis of OAB who initiated antimuscarinic treatment for OAB (fesoterodine, tolterodine, or solifenacin) were included. The first prescription of one of the OAB study medications was considered the index date; patients were followed for ≥52 weeks. Persistence was estimated using Kaplan–Meier curves and Cox proportional hazard regression models, adjusting for covariates.
A total of 1,971 records of patients (58.3 % women; mean age 70.1 years) initiating treatment with fesoterodine (n = 302), solifenacin (n = 952), or tolterodine (n = 717) were included. Unadjusted mean (±SD) treatment duration was 31.5 ± 17.6 weeks for fesoterodine, 29.9 ± 21.4 for solifenacin and 29.0 ± 21.6 for tolterodine (p = 0.217). At week 52, 35.8 % of fesoterodine-treated patients remained on their initial therapy, versus 31.9 % of solifenacin-treated (hazard ratio [HR], 1.24; 95 % CI, 1.05–1.47; p = 0.011) and 30.9 % of tolterodine-treated (HR = 1.28; 95 % CI, 1.07–1.52; p = 0.006) patients. Findings were consistent when the definition for discontinuation was varied.
Overall persistence at week 52 was low, but the cumulative probability of persisting with initial therapy was significantly higher for fesoterodine than for solifenacin or tolterodine in clinical practice in Spain.
KeywordsOveractive bladder Antimuscarinics Fesoterodine Solifenacin Tolterodine Medication persistence
- 25.The International Classification of Primary Care in the European Community: With a Multi-language Layer (1993) Oxford Medical PublicationsGoogle Scholar
- 28.Castro-Diaz D, Miranda P, Sanchez-Ballester F, Lizarraga I, Arumi D, Rejas J (2012) Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study. BMC Urol 12:19PubMedCentralPubMedCrossRefGoogle Scholar